Skip to main content
. 2015 Apr 27;4(7):1091–1100. doi: 10.1002/cam4.453

Figure 4.

Figure 4

Effects of TPX2 silencing on the expression of angiogenesis-associated factors in a xenograft mouse model. (A) Profiling of angiogenesis and antiangiogenesis factors was performed using Human Anginogenesis Arrays in tumors treated with Control siRNA- or TPX2 siRNA-2 in a xenograft mouse model (n = 3 in each group). The expression of IGFBP-3 (circled) was identified in tumors treated with TPX2 siRNA and Control siRNA using the angiogenesis arrays (left). The IGFBP-3 expression levels were shown relative to the levels in tumors treated with Control siRNA (right). *P < 0.05 vs. Control siRNA-treated tumor. (B) The expression of IGFBP-3 and CD34 was analyzed by immunohistochemistry in xenograft tumors treated with either PBS (left), Control siRNA (middle), or TPX2 siRNA (right). The graphs show the proportion of IGFBP-3-positive cells relative to the total number of cells (left) and the number of CD34-positive cells (right) in 10 randomly selected high- power fields per section. *P < 0.05 vs. PBS-treated tumor. **P < 0.05 vs. Control siRNA-treated tumor. TPX2, targeting protein for Xklp2; PBS, phosphate-buffered saline; IGFBP3, insulin-like growth factor-binding protein-3.